Lamictal Antitrust Class Action Paused For Certification Fight
Law360 (March 22, 2019, 7:03 PM EDT) -- A New Jersey federal judge agreed Friday to pause a class action alleging a pay-for-delay scheme over the mood stabilizer Lamictal while GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. fight the case’s class certification in the Third Circuit, despite drug wholesalers' objections to delaying proceedings in the long-running case.
Reconsidering her previous refusal to stay the case pending the Third Circuit appeal, U.S. Magistrate Judge Cathy L. Waldor switched gears Friday after a telephone conference and granted the motions by the drugmakers to put the district court proceedings on hold. Named plaintiffs Louisiana Wholesale Drug Co. Inc., King Drug Co. of...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!